Therapeutic antibodies are often engineered or selected to have high on-target binding affinities that can be challenging to determine precisely by most biophysical methods. Here, we explore the dynamic range of the kinetic exclusion assay (KinExA) by exploiting the interactions of an anti-DKK antibody with a panel of DKK antigens as a model system. By tailoring the KinExA to each studied antigen, we obtained apparent equilibrium dissociation constants (KD values) spanning six orders of magnitude, from approximately 100 fM to 100 nM. Using a previously calibrated antibody concentration and working in a suitable concentration range, we show that a single experiment can yield accurate and precise values for both the apparent KD and the apparent active concentration of the antigen, thereby increasing the information content of an assay and decreasing sample consumption. Orthogonal measurements obtained on Biacore and Octet label-free biosensor platforms further validated our KinExA-derived affinity and active concentration determinations. We obtained excellent agreement in the apparent affinities obtained across platforms and within the KinExA method irrespective of the assay orientation employed or the purity of the recombinant or native antigens.
References
[1]
Glass TR, Ohmura N, Saiki H, Sawadaishi K, Kataoka C, et al. (2004) Development and characterization of new monoclonal antibodies specific for coplanar polychlorinated biphenyls. Analytica Chimica Acta 517: 161–168.
[2]
Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25: 7469–7481. doi:10.1038/sj.onc.1210054.
[3]
Krupnik VE, Sharp JD, Jiang C, Robison K, Chickering TW, et al. (1999) Functional and structural diversity of the human Dickkopf gene family. Gene 238: 301–313.
[4]
Nakamura REI, Hackam AS (2010) Analysis of Dickkopf3 interactions with Wnt signaling receptors. Growth Factors 28: 232–242. doi:10.3109/08977191003738832.
Navratilova I, Eisenstien E, Myszka DG (2005) Measuring long association phases using Biacore. Anal Biochem 344: 295–297. doi:10.1016/j.ab.2005.05.025.
[7]
Darling RJ, Brault P-A (2005) Kinetic Exclusion Assay Technology: Characterization of Molecular Interactions. Assay and Drug Development Technologies 2: 647–657.
[8]
Blake RC 2nd, Pavlov AR, Blake DA (1999) Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution. Anal Biochem 272: 123–134. doi:10.1006/abio.1999.4176.
[9]
Xie L, Mark Jones R, Glass TR, Navoa R, Wang Y, et al. (2005) Measurement of the functional affinity constant of a monoclonal antibody for cell surface receptors using kinetic exclusion fluorescence immunoassay. J Immunol Methods 304: 1–14. doi:10.1016/j.jim.2005.04.009.
[10]
Rathanaswami P, Richmond K, Manchulenko K, Foltz IN (2011) Kinetic analysis of unpurified native antigens available in very low quantities and concentrations. Anal Biochem 414: 7–13. doi:10.1016/j.ab.2011.02.034.
[11]
Blake DA, Chakrabarti P, Khosraviani M, Hatcher FM, Westhoff CM, et al. (1996) Metal Binding Properties of a Monoclonal Antibody Directed toward Metal-Chelate Complexes. Journal of Biological Chemistry 271: 27677–27685. doi:10.1074/jbc.271.44.27677.
[12]
Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, et al. (2005) Molecular Evolution of Antibody Affinity for Sensitive Detection of Botulinum Neurotoxin Type A. Journal of Molecular Biology 351: 158–169. doi:10.1016/j.jmb.2005.06.003.
[13]
Sigmundsson K, Másson G, Rice R, Beauchemin N, Obrink B (2002) Determination of active concentrations and association and dissociation rate constants of interacting biomolecules: an analytical solution to the theory for kinetic and mass transport limitations in biosensor technology and its experimental verification. Biochemistry 41: 8263–8276.
[14]
Katsamba PS, Navratilova I, Calderon-Cacia M, Fan L, Thornton K, et al. (2006) Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. Anal Biochem 352: 208–221. doi:10.1016/j.ab.2006.01.034.
[15]
Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, et al. (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 427: 843–848. doi:10.1038/nature02319.
[16]
Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, et al. (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131: 308–316. doi:10.1016/j.clim.2009.01.002.
[17]
Rathanaswami P, Roalstad S, Roskos L, Su QJ, Lackie S, et al. (2005) Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem Biophys Res Commun 334: 1004–1013. doi:10.1016/j.bbrc.2005.07.002.
[18]
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, et al. (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24: 182–195. doi:10.1359/jbmr.081112.
[19]
Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, et al. (2011) XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs 3: 49–60.
[20]
Khosraviani M, Blake RC, Pavlov AR, Lorbach SC, Yu H, et al. (2000) Binding Properties of a Monoclonal Antibody Directed toward Lead–Chelate Complexes. Bioconjugate Chemistry 11: 267–277. doi:10.1021/bc9901548.
[21]
Fleury D, Gillard C, Lebhar H, Vayssière B, Touitou R, et al. (2008) Expression, purification and characterization of murine Dkk1 protein. Protein Expression and Purification 60: 74–81. doi:16/j.pep.2008.03.023.
